Previous 10 | Next 10 |
NORTH BILLERICA, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions and other factors, $500 million in aggregate principal amount of the C...
NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Figh...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow dis...
What's better than a stock that's a big winner? A stock that's a big winner that should be able to keep on winning in the future. There are more in this category than you might think. The following three stocks are absolutely crushing the market so far this year. And Wall Street thinks ...
Point Biopharma Global's ( NASDAQ: PNT ) stock fell ~35% on Monday after the company said it was selling licensing rights to radiopharmaceutical cancer drug candidates PNT2002 and PNT2003 to Lantheus ( NASDAQ: LNTH ). Upon completion, Lantheus ...
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding cer...
NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,...
Lantheus Holdings, Inc. (LNTH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Mark Kinarney - VP, IR Mary Heino - President and CEO Paul Blanchfield – COO Robert Marshall - CFO and Treasurer Conference Call Part...
Lantheus Holdings ( NASDAQ: LNTH ) dropped ~8% in the morning hours Thursday to reach the lowest level since July, even after the diagnostic compound maker announced better-than-expected Q3 2022 financials and set its outlook ahead of the consensus. Lantheus ( LNTH...
Lantheus press release ( NASDAQ: LNTH ): Q3 Non-GAAP EPS of $0.99 beats by $0.16 . Revenue of $239.29M (+134.4% Y/Y) beats by $11.41M . Net cash provided by operating activities was $93.6 million for the third quarter 2022. Free cash flow was $87.5 million in t...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.4%Change Percent:
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...